Shenzhou Cell announced that Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to carry out clinical trials for type A hemophilia with the SCTB10 injection developed independently. SCTB10 is a recombinant anti-Fixa/FX bispecific antibody injection. This time, it has been approved to conduct a phase I/II clinical study evaluating the subcutaneous administration of this product in healthy volunteers and patients with hemophilia A. There is still uncertainty about whether and when the product will be approved for marketing, and it is expected that it will not have a significant impact on the company's operating performance in the short term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.